Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clozapine + atomoxetine
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Clozapine + atomoxetine** is a combination of two pharmaceutical agents: clozapine, an atypical antipsychotic primarily used for treatment-resistant schizophrenia, and atomoxetine, a selective norepinephrine reuptake inhibitor indicated for attention-deficit/hyperactivity disorder (ADHD). Clozapine acts mainly as an antagonist at dopamine receptor D2 and serotonin receptor 5-HT2A, with additional antagonism at adrenergic, cholinergic, histaminergic, and other dopaminergic/serotonergic receptors. Atomoxetine selectively inhibits the presynaptic norepinephrine transporter to increase synaptic norepinephrine levels. The combination is not standard therapy but may be considered in rare clinical scenarios such as comorbid ADHD in patients with schizophrenia. However, this combination carries a significant risk of QT/QTc prolongation and potentially life-threatening arrhythmias such as torsade de pointes; therefore it should only be used under close medical supervision[1][2][3][4][5].
- Brand names
- FazaClo
- Other names
- clozapine augmented with atomoxetineatomoxetine augmentation of clozapineCAPG Study intervention
02
Targets
HTR2A (5-hydroxytryptamine receptor 2A)NET (Norepinephrine Transporter)DRD2 (Dopamine D2 Receptor)HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on clozapine + atomoxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clozapine + atomoxetine.